Wall Street analysts expect Trevena, Inc. (NASDAQ:TRVN) to post earnings of ($0.31) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Trevena’s earnings. The lowest EPS estimate is ($0.37) and the highest is ($0.24). Trevena posted earnings of ($0.57) per share during the same quarter last year, which suggests a positive year over year growth rate of 45.6%. The firm is scheduled to announce its next earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Trevena will report full-year earnings of ($1.31) per share for the current fiscal year, with EPS estimates ranging from ($1.49) to ($1.14). For the next fiscal year, analysts expect that the company will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.17) to ($0.56). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Trevena.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35).

TRVN has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Trevena from a “hold” rating to a “sell” rating in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. set a $8.00 price objective on Trevena and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, Cowen and Company reissued a “buy” rating and issued a $10.00 price objective on shares of Trevena in a research report on Friday, August 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $10.56.

A number of hedge funds have recently modified their holdings of TRVN. FMR LLC lifted its position in Trevena by 4.5% during the 1st quarter. FMR LLC now owns 7,037,804 shares of the biopharmaceutical company’s stock worth $25,828,000 after acquiring an additional 304,256 shares during the period. Vanguard Group Inc. grew its stake in Trevena by 15.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,822,103 shares of the biopharmaceutical company’s stock valued at $4,191,000 after purchasing an additional 238,089 shares during the last quarter. Northpointe Capital LLC grew its stake in Trevena by 5.0% during the 2nd quarter. Northpointe Capital LLC now owns 1,221,479 shares of the biopharmaceutical company’s stock valued at $2,809,000 after purchasing an additional 58,295 shares during the last quarter. State Street Corp increased its holdings in shares of Trevena by 8.3% in the second quarter. State Street Corp now owns 768,249 shares of the biopharmaceutical company’s stock valued at $1,767,000 after purchasing an additional 58,895 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Trevena by 528.5% in the second quarter. Dimensional Fund Advisors LP now owns 711,615 shares of the biopharmaceutical company’s stock valued at $1,637,000 after purchasing an additional 598,383 shares during the period. Institutional investors own 60.09% of the company’s stock.

WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/04/0-31-eps-expected-for-trevena-inc-trvn-this-quarter.html.

Shares of Trevena (NASDAQ:TRVN) traded down 1.400% during trading on Wednesday, reaching $2.465. The company’s stock had a trading volume of 264,056 shares. The stock’s market capitalization is $147.15 million. Trevena has a 12-month low of $2.15 and a 12-month high of $8.00. The firm’s 50-day moving average is $2.47 and its 200-day moving average is $2.79.

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.